Labrycor (Isoprenaline Hydrochloride)

Isoprenaline Hydrochloride is a non‑selective beta‑adrenergic agonist. It binds to β1 receptors in the heart, increasing cyclic AMP and enhancing pacemaker activity and contractility. Simultaneously, it activates β2 receptors in the lungs, raising cyclic AMP in airway smooth muscle, which leads to bronchodilation. The dual action supports both cardiac and respiratory function.

The appropriate dose of Labrycor is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosing is individualized, and the prescriber will set the infusion rate and duration according to clinical guidelines and monitoring parameters.

Safety data for Isoprenaline Hydrochloride in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers must evaluate each case carefully and discuss potential risks with the patient.

To order Labrycor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Labrycor’s active ingredient, Isoprenaline, is a non‑selective beta‑agonist, whereas alternatives such as epinephrine are also non‑selective but have a stronger alpha‑adrenergic component. Isoprenaline provides more pronounced β2‑mediated bronchodilation with less vasoconstriction, making it preferable when a primary focus on cardiac stimulation and bronchodilation is needed without significant peripheral vasoconstriction.

Labrycor should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Do not freeze. Before use, inspect for particulate matter or discoloration and discard any solution that appears compromised.

Labrycor is supplied as a sterile intravenous solution and is administered by a qualified healthcare professional via controlled IV infusion. The infusion rate is titrated to achieve the desired clinical effect while continuous monitoring of cardiac rhythm, blood pressure, and respiratory status is maintained throughout the administration.

Serious adverse reactions include life‑threatening arrhythmias, myocardial ischemia, and paradoxical severe bronchospasm. Patients may also develop profound tachycardia or hypertension. Immediate medical attention is required if any of these events occur, and continuous cardiac and respiratory monitoring is essential during treatment.

Labrycor is contraindicated in patients with uncontrolled hyperthyroidism, severe hypertension, or known hypersensitivity to isoprenaline or any formulation components. It should also be avoided in individuals taking high‑dose beta‑blockers or those with certain types of cardiac conduction disorders where increased heart rate could be harmful.